A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects wiht moderate to severe chronic plaque-type psoriasis on eiher a fixed dose regimen or on a retreatment at start of relapse regimen Sculpture
Laufzeit: 01.01.2011 - 31.12.2012
imported
Kurzfassung
To evaluate the efficacy of secukinumab treatment regimens in subjects with moderate ot severe chronic plaque psoriasis with respect to PASI 50/75/90/100
